INTRAVENOUS ZOLEDRONIC ACID IN PREVENTING SUBSEQUENT OSTEOPOROTIC FRACTURES

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是确定在两年的时间里，与单独使用维生素D2、维生素D和元素碳酸钙相比，在急性髋部骨折手术修复后服用名为唑来膦酸(双磷酸盐)加维生素D2、维生素D和元素碳酸钙的研究药物是否在降低所有后续骨折的发生率方面更有效。这项研究还将试图确定唑来膦酸对生活质量、日常生活体力活动、身体疼痛和医疗费用(探索性终点)的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether an investigational drug with the name zoledronic acid, (a bisphosphonate) plus, vitamin D2, vitamin D and elemental calcium carbonate given after surgical repair on an acute hip fracture, is more effective in reducing the rate of all subsequent bone fractures compared to vitamin D2, vitamin D and elemental calcium carbonate alone, during a two year period of time. This study will also attempt to determine the effect of zoledronic acid on quality of life, physical activities of daily living, body pain, and medical costs (exploratory endpoints).